Phase 4
Completed N=31
Sugammadex ED90 Dose in the Obese Patients
Incomplete Reversal of Neuromuscular Block
Source: ClinicalTrials.gov NCT02568345 ↗
Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Feb 2016
Primary outcomePrimary: Sugammadex ED90 — 2.40 mg/kg
Summary
The purpose of this study is to determine the minimum effective dose of sugammadex, an antagonist of neuromuscular blockade used during anesthesia practice, in obese patients, considering that sugammadex is indicated in adults with normal weight at a dose of 2 mg/kg but no studies were found with obese patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Sugammadex ED90 |
2.40 | — |
Eligibility Criteria
Inclusion Criteria
- a body mass index ≥ 40 kg/m2
- bariatric surgery
- informed consent signed
Exclusion Criteria
- history of neuromuscular diseases,
- use of drugs that could interfere with neuromuscular transmission,
- allergy to neuromuscular agents of the aminosteroids class,
- anticipated difficulty in airway management,
- renal failure
Data sourced from ClinicalTrials.gov (NCT02568345). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.